Here are some sample widgets you could interact with from this dashboard:
ANALYSIS: Is Pfizer stock expensive based on a review of the fundamentals?
P/E Ratio: Based on trailing 2019 P/E ratios, PFE stock looks attractive compared to prior years and attractive compared to Merck & Co, Inc
Pfizer 2019 trailing P/E ratio of 13.2 is 0.6x that of the 2019 Merck & Co, Inc P/E ratio of 23.3 $.
* P/E Ratio is calculated based on year end market price and trailing earnings. However, for 2020 P/E, we use 2019 earnings and current market price.
Historical Revenue Growth: Pfizer stock looks expensive compared to Merck & Co, Inc
Pfizer 2014-19 annualized revenue growth of 1% is 0.2x that of the 2014-19 S&P 500 annualized revenue growth rate of 3.9%.
2014-19 Annualized Revenue Growth Comparison
Roche Annual Change In Revenue
PFE Annual Change in Revenue
Historical EPS Growth: Pfizer stock looks attractive compared to Merck & Co, Inc
Pfizer 2014-19 annualized EPS growth of 15% is 2.7x that of the 2014-19 S&P 500 annualized EPS growth rate of 5.7%.
2014-19 Annualized EPS Growth Comparison
RHHBY Adjusted EPS Growth
PFE Adjusted EPS Growth
Survival Check: Total Debt Comparisons
Pfizer Total Debt has increased from $x to $y between 2016 and 2019. In comparison, Total Debt for Merck & Co, Inc has risen from $x to $y.
RHHBY Total Debt
PFE Total Debt